These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12355388)

  • 1. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation.
    Zaia JA
    Clin Infect Dis; 2002 Oct; 35(8):999-1004. PubMed ID: 12355388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation.
    Zaia JA
    Bone Marrow Transplant; 2002 Apr; 29(8):633-8. PubMed ID: 12180106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus infection following stem cell transplantation.
    Einsele H; Hebart H
    Haematologica; 1999 Jun; 84 Suppl EHA-4():46-9. PubMed ID: 10907466
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.
    Boeckh M; Nichols WG; Papanicolaou G; Rubin R; Wingard JR; Zaia J
    Biol Blood Marrow Transplant; 2003 Sep; 9(9):543-58. PubMed ID: 14506657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ganciclovir-resistant cytomegalovirus.
    Legendre C
    Lancet; 2000 Oct; 356(9238):1356. PubMed ID: 11073050
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized trial of pre-emptive or prophylactic valganciclovir therapy for prevention of cytomegalovirus infection in renal transplantation.
    Santos RD; Brennan DC
    J Am Soc Nephrol; 2012 Sep; 23(9):1446-8. PubMed ID: 22878958
    [No Abstract]   [Full Text] [Related]  

  • 7. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
    Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
    Chakrabarti S; Collingham KE; Osman H; Fegan CD; Milligan DW
    Bone Marrow Transplant; 2001 Nov; 28(9):879-81. PubMed ID: 11781649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation.
    Crippa F; Corey L; Chuang EL; Sale G; Boeckh M
    Clin Infect Dis; 2001 Jan; 32(2):214-9. PubMed ID: 11170910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
    Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
    J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
    Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.
    Reischig T
    Expert Rev Anti Infect Ther; 2012 Jan; 10(1):51-61. PubMed ID: 22149614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
    Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K
    Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A; de Fabritiis P; Ghisetti V; Allice T; Mirabile M; Gentile G; Locatelli F; Falda M
    Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
    Vusirikala M; Wolff SN; Stein RS; Brandt SJ; Morgan DS; Greer JP; Schuening FG; Dummer JS; Goodman SA
    Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
    Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.